Profusa Raised $45M To Market PAD-Monitoring Implant In Europe
Executive Summary
Digital Health company Profusa raised more than $45m in a series C financing round. The company plans to use the proceeds to bring its tiny CE-marked injectable biosensors, used to monitor tissue oxygenation in patients with peripheral artery disease, to key opinion leaders and clinicians in Europe.
You may also be interested in...
Podcast: Beyond Wearables--Profusa CEO Discusses Novel Tiny Injectable Biosensor For Long-Term Monitoring
In this podcast interview with Medtech Insight, Profusa Inc. Chairman and CEO Ben Hwang discusses the company's long-term biochemical monitoring platform, the first application for its tiny injectable biosensor, and what's next for the company.
Menopause Research To Benefit From White House Initiative To Bolster Women’s Health
Women’s health leaders in the menopause space have high hopes that President Biden’s executive order will provide dollars for more research on how hormone therapy can prevent disease and draw attention to the need for provider education on menopausal symptoms.
BD’s CTO Beth McCombs Discusses Key Initiatives – AI/Gen AI; DE&I Strategy; Succession Planning
BD CTO Beth McCombs discusses her role in driving innovation, including the integration of AI and generative AI to create efficiencies, and passion for creating a culture of inclusion, diversity and equity.